Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.55 +1.2%	$6.61	$4.34 ▼ $12.38	$406.89M	0.46	162,914 shs	200,421 shs
BHVN Biohaven	$15.62 +6.4%	$14.41	$12.79 ▼ $55.70	$1.65B	0.98	2.38 million shs	5.70 million shs
CDTX Cidara Therapeutics	$66.37 -1.7%	$53.69	$10.14 ▼ $69.36	$1.68B	1.18	435,850 shs	558,355 shs
IMCR Immunocore	$32.93 +0.8%	$33.30	$23.15 ▼ $39.33	$1.66B	0.77	331,828 shs	289,496 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-2.53%	-7.22%	+11.21%	-14.94%
BHVN Biohaven	0.00%	-0.54%	+13.94%	-0.34%	-62.18%
CDTX Cidara Therapeutics	0.00%	+1.78%	+5.65%	+173.35%	+410.54%
IMCR Immunocore	0.00%	+0.15%	-6.63%	+5.68%	-9.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	1.8351 of 5 stars	3.6	0.0	0.0	2.6	2.5	0.0
BHVN Biohaven	3.8222 of 5 stars	4.5	3.0	0.0	2.9	2.5	0.6
CDTX Cidara Therapeutics	3.5408 of 5 stars	2.6	3.0	4.6	2.2	1.7	0.0
IMCR Immunocore	1.7738 of 5 stars	3.3	1.0	0.0	2.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.11	Buy	$22.00	235.88% Upside
BHVN Biohaven	3.07	Buy	$54.23	247.28% Upside
CDTX Cidara Therapeutics	3.11	Buy	$64.14	-3.36% Downside
IMCR Immunocore	2.50	Moderate Buy	$58.00	76.13% Upside

Current Analyst Ratings Breakdown

Latest AURA, BHVN, IMCR, and CDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	AURA Aura Biosciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/19/2025	BHVN Biohaven	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$59.00 ➝ $60.00
8/13/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
8/12/2025	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $30.00
8/12/2025	BHVN Biohaven	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $50.00
8/12/2025	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$63.00 ➝ $54.00
8/12/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $52.00
8/12/2025	BHVN Biohaven	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $49.00
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$2.81 per share	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	$1.27 per share	N/A
CDTX Cidara Therapeutics	$1.27M	1,325.31	N/A	N/A	$19.76 per share	3.36
IMCR Immunocore	$310.20M	5.35	N/A	N/A	$7.71 per share	4.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.96	N/A	N/A	N/A	N/A	-64.44%	-54.24%	11/11/2025 (Estimated)
BHVN Biohaven	-$846.42M	-$7.66	N/A	N/A	N/A	N/A	-270.65%	-143.70%	11/11/2025 (Estimated)
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	11/6/2025 (Estimated)
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)

Latest AURA, BHVN, IMCR, and CDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AURA Aura Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
8/11/2025	Q1 2025	BHVN Biohaven	-$1.94	-$1.94	N/A	-$1.94	$0.41 million	N/A
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	12.39	12.39
BHVN Biohaven	1.91	3.82	3.82
CDTX Cidara Therapeutics	N/A	16.45	16.45
IMCR Immunocore	1.01	5.89	5.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
BHVN Biohaven	88.78%
CDTX Cidara Therapeutics	35.82%
IMCR Immunocore	84.50%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	6.30%
BHVN Biohaven	16.00%
CDTX Cidara Therapeutics	3.89%
IMCR Immunocore	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	62.12 million	58.21 million	Not Optionable
BHVN Biohaven	239	105.79 million	88.86 million	Optionable
CDTX Cidara Therapeutics	90	25.36 million	24.37 million	No Data
IMCR Immunocore	320	50.39 million	45.15 million	Optionable

AURA, BHVN, IMCR, and CDTX Headlines

Recent News About These Companies

T. Rowe Price Investment Management Inc. Buys 351,610 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

August 23 at 6:45 AM | marketbeat.com

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Moderate Buy" by Analysts

August 19, 2025 | marketbeat.com

Q3 Earnings Forecast for Immunocore Issued By HC Wainwright

August 16, 2025 | marketbeat.com

What is HC Wainwright's Estimate for Immunocore Q3 Earnings?

August 16, 2025 | americanbankingnews.com

Immunocore FY2027 EPS Forecast Increased by HC Wainwright

August 15, 2025 | marketbeat.com

FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright

August 14, 2025 | americanbankingnews.com

Persistent Asset Partners Ltd Purchases New Stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

August 13, 2025 | marketbeat.com

Immunocore’s Earnings Call Highlights Robust Growth and Strategic Expansion

August 13, 2025 | msn.com

Immunocore Holdings plc (NASDAQ:IMCR) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Immunocore (NASDAQ:IMCR) Cut to Hold at Wall Street Zen

August 10, 2025 | marketbeat.com

Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

Immunocore Holdings plc 2025 Q2 - Results - Earnings Call Presentation

August 9, 2025 | seekingalpha.com

Immunocore Holdings PLC (IMCR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...

August 8, 2025 | finance.yahoo.com

Immunocore (IMCR) Q2 Revenue Jumps 30%

August 8, 2025 | aol.comA

Primecap Management Co. CA Increases Position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

August 8, 2025 | marketbeat.com

Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics

August 7, 2025 | zacks.com

Immunocore reports second quarter financial results and provides a business update

August 7, 2025 | globenewswire.com

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Shares Sold by BIT Capital GmbH

August 4, 2025 | marketbeat.com

TD Asset Management Inc Reduces Position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

August 2, 2025 | marketbeat.com

Immunocore (IMCR) Expected to Announce Quarterly Earnings on Thursday

August 1, 2025 | marketbeat.com

Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

July 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AURA, BHVN, IMCR, and CDTX Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.55 +0.08 (+1.24%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.55 0.00 (0.00%)

As of 08/22/2025 06:45 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Biohaven NYSE:BHVN

$15.62 +0.94 (+6.38%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$15.68 +0.06 (+0.40%)

As of 08/22/2025 07:56 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Cidara Therapeutics NASDAQ:CDTX

$66.37 -1.12 (-1.66%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$66.87 +0.50 (+0.75%)

As of 08/22/2025 06:08 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Immunocore NASDAQ:IMCR

$32.93 +0.26 (+0.80%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$33.01 +0.08 (+0.23%)

As of 08/22/2025 04:10 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time